IRD
What one share of Opus Genetics holds
Pharmaceutical Preparations
Opus Genetics, Inc. (the “Company,” “Opus,” “we,” “us,” or “our”) is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent
Opus Genetics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.12 |
|---|---|
| Profit | −$1.29 |
| Cash and investments | $1.07 |
| Debt | $0.43 |
| Book value | −$0.16 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$0.43 | — | −$0.61 | — | $0.72 |
| 2017 | — | −$0.92 | — | −$0.56 | — | $0.53 |
| 2018 | — | −$5.25 | — | −$6.88 | — | −$0.54 |
| 2019 | $1.05 | −$2.17 | $0.01 | −$1.27 | — | −$2.65 |
| 2020 | $0.00 | −$5.28 | $0.00 | −$1.46 | — | — |
| 2021 | $0.04 | −$3.82 | — | −$1.30 | — | $1.18 |
| 2022 | $1.93 | $0.87 | — | $0.69 | — | $2.22 |
| 2023 | $0.88 | −$0.46 | — | −$0.05 | — | $2.08 |
| 2024 | $0.41 | −$2.15 | — | −$0.96 | — | $0.21 |
| 2025 | $0.23 | −$0.80 | — | −$0.57 | — | $0.22 |